Literature DB >> 21683825

Testosterone deficiency.

Abdulmaged M Traish1, Martin M Miner, Abraham Morgentaler, Michael Zitzmann.   

Abstract

Testosterone deficiency (TD) afflicts approximately 30% of men aged 40-79 years, with an increase in prevalence strongly associated with aging and common medical conditions including obesity, diabetes, and hypertension. A strong relationship is noted between TD and metabolic syndrome, although the relationship is not certain to be causal. Repletion of testosterone (T) in T-deficient men with these comorbidities may indeed reverse or delay their progression. While T repletion has been largely thought of in a sexual realm, we discuss its potential role in general men's health concerns: metabolic, body composition, and all-cause mortality through the use of a single clinical vignette. This review examines a host of studies, with practical recommendations for diagnosis of TD and T repletion in middle-aged and older men, including an analysis of treatment modalities and areas of concerns and uncertainty.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21683825     DOI: 10.1016/j.amjmed.2010.12.027

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  48 in total

1.  Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial.

Authors:  Seng-Fah Tong; Chirk-Jenn Ng; Boon-Cheok Lee; Verna-K M Lee; Ee-Ming Khoo; Eng-Giap Lee; Hui-Meng Tan
Journal:  Asian J Androl       Date:  2012-05-28       Impact factor: 3.285

Review 2.  The evaluation and management of testosterone deficiency: the new frontier in urology and men's health.

Authors:  William P Conners; Abraham Morgentaler
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

3.  Fertility Related Quality of Life, Gonadal Function and Erectile Dysfunction in Male Partners of Couples with Unexplained Infertility.

Authors:  R Matthew Coward; Christy Stetter; Allen Kunselman; J C Trussell; Mark C Lindgren; Ruben R Alvero; Peter Casson; Gregory M Christman; Christos Coutifaris; Michael P Diamond; Karl R Hansen; Stephen A Krawetz; Richard S Legro; Randal D Robinson; James F Smith; Anne Z Steiner; Robert A Wild; Heping Zhang; Nanette Santoro
Journal:  J Urol       Date:  2019-07-08       Impact factor: 7.450

4.  Trends and Patterns of Testosterone Therapy among U.S. Male Medicare Beneficiaries, 1999 to 2014.

Authors:  Cindy Ke Zhou; Shailesh Advani; Matthew Chaloux; James Todd Gibson; Mandi Yu; Marie Bradley; Robert N Hoover; Michael B Cook
Journal:  J Urol       Date:  2020-01-13       Impact factor: 7.450

5.  Andrology: Testosterone and cardiovascular risk--deciphering the statistics.

Authors:  Abraham Morgentaler; Ravi Kacker
Journal:  Nat Rev Urol       Date:  2014-02-18       Impact factor: 14.432

6.  Effects of testosterone supplement treatment in hypogonadal adult males with T2DM: a meta-analysis and systematic review.

Authors:  Jianzhong Zhang; Bin Yang; Wenhui Xiao; Xiao Li; Hongjun Li
Journal:  World J Urol       Date:  2018-03-06       Impact factor: 4.226

Review 7.  Testosterone Therapy in Men With Prostate Cancer.

Authors:  Alan L Kaplan; Jim C Hu; Abraham Morgentaler; John P Mulhall; Claude C Schulman; Francesco Montorsi
Journal:  Eur Urol       Date:  2015-12-21       Impact factor: 20.096

8.  Clinically occult prostate cancer cases may distort the effect of testosterone replacement therapy on risk of PCa.

Authors:  Xiao Zhang; Yan Zhong; Farid Saad; Karim Haider; Ahmad Haider; Xiaohui Xu
Journal:  World J Urol       Date:  2019-01-18       Impact factor: 4.226

9.  Revisiting hyper- and hypo-androgenism by tandem mass spectrometry.

Authors:  Flaminia Fanelli; Alessandra Gambineri; Marco Mezzullo; Valentina Vicennati; Carla Pelusi; Renato Pasquali; Uberto Pagotto
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

10.  Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.

Authors:  A Morgentaler; J McGettigan; Q Xiang; T M Danoff; E M Gould
Journal:  Int J Impot Res       Date:  2014-07-24       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.